Obrador G T, Zeigler Z R, Shadduck R K, Rosenfeld C S, Hanrahan J B
Western Pennsylvania Cancer Institute, West Penn Hospital, Pittsburgh 15224.
Am J Hematol. 1993 Feb;42(2):217-20. doi: 10.1002/ajh.2830420214.
This report describes objective improvement in two patients with poorly responsive thrombotic thrombocytopenic purpura (TTP) syndromes (with cryosupernatant). The first had a partial response to plasma exchange with whole plasma (fresh frozen plasma; FFP) and responded dramatically when switched to plasma exchange with cryosupernatant replacement. The second had chronic TTP (three relapses in 9 months) that required prolonged courses of exchange with FFP (approximately 1 month each) to achieve remission. Attempts to manage her recurrent TTP with infusion of two units of FFP had been unsuccessful. The latter patient was tried on cryosupernatant infusions (2 units daily) and responded within 4 days. Moreover, she has been in continuous remission for 12 months while receiving 2 units (one to three times per week). These results suggest that cryoprecipitate-poor plasma may offer advantages over whole plasma in the management of both acute and chronic forms of TTP.
本报告描述了两名对血栓性血小板减少性紫癜(TTP)综合征反应不佳(伴有冷上清液)患者的客观改善情况。第一名患者对用全血浆(新鲜冰冻血浆;FFP)进行血浆置换有部分反应,而改用冷上清液置换进行血浆置换时反应显著。第二名患者患有慢性TTP(9个月内复发3次),需要长时间使用FFP进行置换疗程(每次约1个月)才能实现缓解。尝试通过输注两单位FFP来治疗其复发性TTP未成功。后一名患者试用了冷上清液输注(每日2单位),并在4天内出现反应。此外,她在接受2单位(每周一至三次)治疗期间持续缓解了12个月。这些结果表明,在急性和慢性TTP的治疗中,缺乏冷沉淀的血浆可能比全血浆更具优势。